Evidence map›Paper›PMID 35364768›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

Bilateral facial palsy after COVID-19 vaccination.

Valentina Andreozzi, Beatrice D'arco, Pasquale Pagliano, Antonella Toriello, Paolo Barone

Open access · hybridAbstract read
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Valentina Andreozzi *Neurology Unit, Department of Medicine and Surgery, "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Beatrice D'arco *Neurology Unit, Department of Medicine and Surgery, "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Pasquale PaglianoInfective Disease Unit, Department of Medicine and Surgery, Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Antonella TorielloNeurology Unit, Department of Medicine and Surgery, "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy.
Paolo BaroneNeurology Unit, Department of Medicine and Surgery, "Scuola Medica Salernitana", University of Salerno, Fisciano, Italy. pbarone@unisa.it.ORCID http://orcid.org/0000-0001-8965-2504
University of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guillain-Barrè syndrome (GBS) is an acute immune-mediated neuropathy, possibly triggered by a recent infection or vaccination, and driven by an immune attack targeting the peripheral nervous system. GBS typically leads to ascending limb weakness, often with sensory and cranial nerve involvement 1-2 weeks after immune stimulation, but emergency and neurology physicians should be aware of its important clinical heterogeneity. In rare cases, bilateral facial nerve palsy can be the main clinical manifestation, as the case of the variant formerly known as bilateral facial weakness with paresthesias. An increasing number of case reports of GBS in patients receiving COVID-19 vaccination have been reported both during the pre-clinical phase and after large-scale authorities' approval. We report two cases of bifacial palsy with paresthesias, a rare variant of GBS, both occurring after the first dose of COVID-19 vaccine Vaxzevria™ (formerly COVID-19 vaccine AstraZeneca), showing a favorable outcome after high-dose immunoglobulin therapy, and discuss the literature of GBS post-COVID-19 vaccination.

Indexed as

COVID-19Facial ParalysisGuillain-Barre SyndromeCOVID-19 VaccinesHumansParesthesiaVaccinationCOVID-19 VaccinesBifacial weaknessCOVID-19 vaccinationGuillain-Barré syndrome

Identifiers

PMID35364768
PMCPMC8973678
OpenAlexW4220849855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.